1. Home
  2. USNA vs LCTX Comparison

USNA vs LCTX Comparison

Compare USNA & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo USANA Health Sciences Inc.

USNA

USANA Health Sciences Inc.

HOLD

Current Price

$19.06

Market Cap

317.0M

Sector

Health Care

ML Signal

HOLD

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.64

Market Cap

391.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
USNA
LCTX
Founded
1992
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
317.0M
391.1M
IPO Year
1996
1996

Fundamental Metrics

Financial Performance
Metric
USNA
LCTX
Price
$19.06
$1.64
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$5.33
AVG Volume (30 Days)
109.5K
1.0M
Earning Date
05-05-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.58
N/A
Revenue
$1,060,902,000.00
$14,556,000.00
Revenue This Year
$3.90
$109.40
Revenue Next Year
$6.21
N/A
P/E Ratio
$32.59
N/A
Revenue Growth
N/A
53.24
52 Week Low
$16.60
$0.40
52 Week High
$38.32
$2.09

Technical Indicators

Market Signals
Indicator
USNA
LCTX
Relative Strength Index (RSI) 60.35 54.06
Support Level $18.67 $1.56
Resistance Level $21.35 $1.82
Average True Range (ATR) 0.56 0.08
MACD 0.29 0.02
Stochastic Oscillator 98.19 74.47

Price Performance

Historical Comparison
USNA
LCTX

About USNA USANA Health Sciences Inc.

Usana Health Sciences Inc is a direct selling and direct-to-consumer nutrition, personal health and wellness company. It developed and manufactured science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness. The company has two reportable segments: direct selling and Hiya direct-to-consumer. The direct selling segment develops and manufactures high quality, science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness in various geographic markets that are distributed through the direct selling channel. The Hiya direct-to-consumer segment is a provider of children's health and wellness products in the U.S. Key revenue is generated from Direct selling segment.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.

Share on Social Networks: